C-MER Medical Holdings Limited reported a minor reduction in its issued share capital following an on-market buyback executed on 12 October 2026 under its approved share-repurchase mandate.

• Transaction details – Volume repurchased: 60,000 ordinary shares, representing 0.005 % of the company’s issued shares (excluding treasury shares) prior to the transaction. – Price range: HKD 0.75 to HKD 0.76 per share, with a volume-weighted average of HKD 0.7525. – Total consideration: HKD 0.05 million.

• Post-transaction capital structure (12 October 2026) – Issued shares outstanding (excluding treasury shares): 1.20705 billion, down from 1.20711 billion. – Treasury share balance: 25.29 million, up from 25.23 million. – Total issued shares (including treasury): unchanged at 1.23234 billion.

• Repurchase capacity – The buyback forms part of the general mandate approved on 20 May 2026, which authorises the company to repurchase up to 123.23 million shares. – C-MER Medical has now utilised roughly 0.05 % of this limit. – In line with Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 11 November 2026.

The company confirmed that the repurchase complied with the Hong Kong Stock Exchange’s Main Board requirements and that no material changes have been made to the previously published explanatory statement regarding its share-buyback programme.